Lilly Cymbalta Clears FDA For Diabetes-Related Neuropathic Pain After Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales reps will start promoting the neuropathic pain indication to neurologists and pain specialists in the fourth quarter. After Lilly is confident duloxetine has been appropriately positioned as an antidepressant, a more active marketing of the neuropathic pain indication to primary care physicians will begin.
You may also be interested in...
Lilly’s Cymbalta Gets Generalized Anxiety Disorder Indication
Lilly continues to evaluate the “marketing mix” for the serotonin-norepinephrine reuptake inhibitor, firm tells “The Pink Sheet” DAILY.
Lilly’s Cymbalta Gets Generalized Anxiety Disorder Indication
Lilly continues to evaluate the “marketing mix” for the serotonin-norepinephrine reuptake inhibitor, firm tells “The Pink Sheet” DAILY.
DOV Out-Licenses Pain Candidate Bicifadine To XTL
XTL shifts bicifadine’s development away from “novel indications in acute and chronic pain” to neuropathic pain, firm says.